Received Feb 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | en9581 | IM / UN |
Reported Symptoms: 10038678:RESPIRATORY DEPRESSION; 10067923:VACCINE BREAKTHROUGH INFECTION; Narrative: Patient received two doses of Pfizer COVID-19 vaccine (01/27/2021 & 02/19/2021). On 09/20/2021 patient presented to the ED for chief complain of back pain due to frequent falls. Patient was sent home with Tylenol and cyclobenzaprine. A COVID-19 sample was taken at this time. Patient presented to the ED again on 09/24/2021 with a chief complain of weakness. Labs were reviewed, patient was COVID positive. Patient was admitted, received a four day course of dexamethasone 6mg daily, 2L of oxygen and was empirically treated with ceftriaxone 2g. Patient returned to baseline and was discharged 10/01/2021. Other Relevant HX: Pfizer COVID-19 vaccine dose #1 (01/27/2021) Pfizer COVID-19 vaccine dose #2 (02/19/2021) Problem list significant for: CHF, COPD, CAD, OSA, HTN, obesity Other: Breakthrough COVID-19 infection
Positive COVID-19 PCR (nasopharynx) test 09/20/2021